Farringdon Capital, Ltd. Blueprint Medicines Corp Transaction History
Farringdon Capital, Ltd.
- $198 Billion
- Q1 2025
A detailed history of Farringdon Capital, Ltd. transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Farringdon Capital, Ltd. holds 4,553 shares of BPMC stock, worth $452,977. This represents 0.2% of its overall portfolio holdings.
Number of Shares
4,553Holding current value
$452,977% of portfolio
0.2%Shares
1 transactions
Others Institutions Holding BPMC
# of Institutions
394Shares Held
68.3MCall Options Held
1.54MPut Options Held
1.08M-
Black Rock Inc. New York, NY6.65MShares$661 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.64MShares$661 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.42MShares$539 Million0.06% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.85MShares$383 Million5.51% of portfolio
-
Wellington Management Group LLP Boston, MA3.07MShares$306 Million0.05% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.94B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...